Any adverse events Up to 12 weeks' · Patients with acute low‐back pain
Paracetamol showed no clear difference in any adverse events Up to 12 weeks' compared with placebo (high certainty).
1 finding from 1 review
Adverse events (overall incidence) · patients with upper gastrointestinal bleeding and liver diseases.
Recombinant human factor VII activated showed no clear difference in adverse events (overall incidence) compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events (6–10 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in serious adverse events (6–10 weeks) compared with placebo (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Oral small molecule inhibitors… showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Topical small molecule inhibitors… changes incidence of serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab showed no clear difference in adverse events: all grade by week 8 compared with placebo (low certainty).
1 finding from 1 review
Adverse events: malignancy · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether immunosuppressive treatment changes adverse events: malignancy at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (very low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (1.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review
Adverse events: haemorrhagic stroke · healthy people
Vitamin E leads to higher adverse events: haemorrhagic stroke compared with placebo (high certainty).
1 finding from 1 review
Adverse events related to treatment · adults with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · children and adults with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · non‐ambulatory children and adolescents with SMA types II and III
Oral olesoxime probably leads to lower adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events related to treatment · children with SMA type II
Oral phenylbutyrate probably leads to higher adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events related to treatment · children and adults with SMA types II and III
Subcutaneous somatotropin showed no clear difference in adverse events related to treatment compared with placebo (low certainty).
1 finding from 1 review
RR 1.57 [0.78, 3.17]
19 participants
Low
Adverse events related to treatment · children with SMA types II and III
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low